Scancell (SCLP.PL), the developer of therapeutic cancer and infectious disease vaccines based on its
patented ImmunoBody® platform, is pleased to announce the interim results for the six month period ended 31st October 2009 (‘the period’).
Post Period Highlights:
David Evans, Non-Executive Chairman of Scancell, commented:
“The Company is on track with its clinical programme as outlined in our admission document in 2008, and we look forward to further progress during the current year, as SCIB1 enters Phase I clinical trials.”
A copy of this announcement is available for download at Announcement
The interim financial information is not audited.
For further information contact:
Professor Lindy Durrant - Scancell Holdings Plc - +44 (0)207 245 1100
Kirsty Corcoran/ - Hansard Communications - +44 (0)207 245 1100
John Bick +44 (0)7515 588 947
Ross Andrews - Zeus Capital - +44 (0)161 831 1512
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Mon, 20 May 2019 09:51:00
Sign up to our newsletter to stay up to date with Scancell